C stands for cancer by Saliba, Mario
personal experIence
last year I read the editorial of The Synapse Journal,  ‘C stands for Cancer … Colleagues … Compassion.’1 This has motivated me to narrate my personal experience …
All doctors from time to time deal with harrowing stories of 
patients being struck with serious illness and cancer. Like many, 
I had coped with these experiences during my thirty three years 
as a family doctor by adopting a firm belief that it could never 
happen to me.
Unsurprising then, my sense of shock when, a few months 
ago late in the afternoon I received the results of my second 
prostate biopsy. If I am totally honest, I knew what was coming 
as I have a strong family history of prostate cancer. Initially 
the MRI scan had left me with some hope as the report read ‘a 
suspicious lesion’ and a follow-up was suggested. So I had clung 
to the slim hope it was just a big scare. I was still in denial that 
it can happen to me and hoped that although it could happen it 
was not now but at some later stage in life.
The best thing I did was that I stopped acting as a doctor 
and I submitted myself to the full guidance of my consultant 
and started to act as a patient. Honestly, it was impossible 
to completely block out my professional background. I 
would worry about a suspicious lesion on the MRI, the first 
normal biopsy and make (incorrect) assumptions about the 
significance of a normal blood test result, as the PSA was never 
more than 3.1 (monitored over a period of five years). I still 
remembered lecturers and clinicians telling us during our 
semiotics tutorials many years ago that disease manifests itself 
differently in different people even though we label it with 
the same name. I continued with my consultations or rather 
discussions, as I should say that my consultant always involved 
me in resolving the issue until a full diagnosis was made. So 
with a bit more persistance from my end and gentle patience 
from my consultant, a repeat guided biopsy was made and left 
me with no doubt. 
Despite years of training in clinical communication skills, 
I now know how it is that patients only recall the first sentence 
when bad news is broken. “I have the results of your biopsy and 
I am afraid it is not good news”, was what I heard my consultant 
say on the mobile. I had been diagnosed with prostate cancer. 
The surgeon reassured me that it was not bad as it was at an 
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discontinue Seretide, assess patient and give alternative therapy if necessary. Systemic effects may occur with any 
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fluticasone propionate in plasma, therefore avoid concomitant use. There is also an increased risk of systemic side 
effects with other potent CYP3A inhibitors. There was an increased reporting of lower respiratory tract infections 
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early stage. He encouraged me to talk to the pathologist to 
get it explained and he made me an appointment to discuss it 
face-to-face with him and bring over my wife. Despite all the 
reassurances I got from both, the rest of the call passed in a blur. 
In that moment it felt like my whole identity had been turned 
on its head. I was no longer a doctor, I was a cancer patient with 
all the fears and questions that anyone faced with that diagnosis 
experiences: how will I cope? Who will look after the family? 
What will happen with work? Will my wife manage? Will I die? 
I imagined the worst scenario possible. Then the doctor in me 
took over again. I started looking up the medical literature about 
the management of early prostate cancer. On one occasion, I 
stumbled across a paper in a clinical journal about complications 
from the treatment of prostate cancer and made the mistake 
of reading it. The verdict from the literature review was not 
clear and I knew that I had three choices, active surveillance, 
and radical prostatectomy or localised brachytherapy. I had 
already made up my mind and my view was respected by the 
consultant but he acted very professionally and suggested that 
he presents my case in a multi-disciplinary meeting which 
is an indispensable aid to communication between different 
specialities. He also reminded me of all the possible side effects 
and complications from the treatments. Perhaps I was hoping 
for reassurance, but the stark facts in front of me had the 
opposite effect. I learned my lesson, and avoided reading articles 
about my condition and over-analysing my blood tests or scan 
results. From then on, I wanted nothing more than to hand over 
that responsibility to the experts.
Patient choice is an important consideration in the type of 
treatment given provided this is available locally but if there is 
a specialised treatment that is indicated the team of consultants 
will recommend that you are sent abroad. Although I knew 
what the options for me were, more important still was having 
confidence in the expertise of those around me to make the 
right decisions on my behalf. I consider myself fortunate in that 
I knew what was happening and what path I will eventually 
follow. How much harder it must be for most patients who must 
put blind faith in those around them!
In my case the multi-disciplinary team of consultants 
recommended robotic surgery and this was my decision 
to follow from the first days of thinking about treatment. 
Unfortunately this specialised type of keyhole surgery is not 
available in Malta. So they sent all my results to a specialised 
hospital in London where they carry out this type of operation. 
A few weeks later we received confirmation that they agreed and 
they were booking me for surgery in the UK. 
During all this process, however, by necessity my anonymity 
could not be maintained in its entirety. All my results were 
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on the IT hospital system. My case was discussed at multi-
disciplinary meetings and I sometimes wondered if the 
colleagues I walked past knew about my diagnosis. I continue to 
avoid being the patient until the last week I left for treatment. In 
England the environment was completely different. I was just a 
patient. Although the doctors knew that I was myself a doctor 
all other staff didn’t know and I just let them do their job as 
professionals. I should say that seven out of ten of the hospital 
staff were foreigners from different European countries, Africa 
or South America. The common thing between them is that they 
respect the dignity of the patient and they all maintain the same 
high standards of care. 
In a time of bewildering uncertainty, the knowledge that 
the NHS machinery would kick into action and be there for 
you is hugely reassuring. Within a few weeks I was laying 
inside the Isotope scanner unit for a whole body CT scan, 
getting further tests to stage my cancer. The efficiency and 
professionalism with which my case was handled lived up 
to high standards. We hear so much about the failings of 
the UK’s NHS in the tabloids that the many small daily 
achievements when things go as planned often pass by 
unnoticed. Our health system is one of the best in the world. 
It is complimented by special agreements with different 
specialised hospitals so that the most up-to-date treaments 
are provided to all Maltese and Gozitan patients free of 
charge at the point of use. 
Everyone who strives to provide gold-standard treatment 
within the NHS knows that what matters is that patients receive 
the most modern treatment in a timely fashion. But as a patient 
I also learned that the small things matter too. Like a friendly 
word from the nurse looking after you during your stay in the 
hospital after surgery, or the secretary you call to check on your 
next appointment, or even like clear signposting indicating the 
out-patients or urology department. All of these things help to 
smooth the patient’s journey in a way that is difficult to quantify.
I have completed my treatment now and have made the testing 
transition back to work. I am able to reflect on the lessons I have 
learned in the last year or so and the unexpected insights that I will 
take forward with me as a doctor. As I look towards the future as 
a doctor I hope to put to good use the lessons I have learned as a 
patient. I end this narration with a quotation included in the related 
editorial of The Synapse Journal1 which I mentioned in the opening 
paragraph … True compassion means not only feeling another’s pain 
but also being moved to help relieve it (Daniel Goleman). 
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